Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab plus paclitaxel/carboplatin versus placebo plus paclitaxel/carboplatin in stage IV or recurrent squamous NSCLC
NL-OMON39194Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) and Pulmonary squamous cell carcinoma comparing Ipilimumab + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoint: Overall survival in squamous population. Started Aug 2011; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON39194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39194.